Aureobasidium Pullulans Var. Pullutans

Dosage for Aureobasidium Pullulans Var. Pullutans must be highly individualized based on the patient's sensitivity level and clinical response.

• Diagnostic Testing: For prick testing, a single drop of the 1:10 or 1:20 w/v concentrate is applied. For intradermal testing, 0.02 to 0.05 mL of a 1:1,000 or 1:10,000 w/v dilution is injected.
• Immunotherapy (Build-up Phase): Typically starts with a very low dose, such as 0.05 mL of a 1:100,000 w/v dilution, increasing weekly or bi-weekly by 50% to 100% as tolerated.
• Maintenance Phase: Once the 'top dose' is reached (often 0.5 mL of a 1:10 or 1:20 w/v solution), the interval between injections is increased to every 2 to 4 weeks.

Aureobasidium Pullulans Var. Pullutans is generally considered safe for use in children, typically starting at age 5. Dosing follows the same weight/volume titration as adults but requires even more cautious observation due to the smaller physical size of the patient and potential difficulty in communicating early symptoms of systemic reactions. Children under age 5 are rarely candidates for immunotherapy unless the allergic disease is severe and other options have failed.

Renal Impairment

No specific dosage adjustments are required for patients with renal impairment, as the protein load is minimal. However, overall health should be stable before administration.

Hepatic Impairment

No dosage adjustments are necessary for hepatic impairment. The metabolism of allergenic proteins is not dependent on cytochrome P450 pathways.

Elderly Patients

Elderly patients may have a higher risk of cardiovascular complications if a systemic reaction occurs. Healthcare providers may choose a more conservative build-up schedule and must carefully evaluate the patient's use of beta-blockers, which are often contraindicated during immunotherapy.

This medication is NEVER self-administered at home. It must be administered in a clinical setting equipped with emergency resuscitation equipment.

• Preparation: The vial should be inspected for particulate matter or discoloration. It is typically stored at 2°C to 8°C (36°F to 46°F).
• Administration: Subcutaneous injection is usually given in the posterior aspect of the upper arm. The site should be rotated between the left and right arms with each visit.
• Observation: Patients MUST remain in the clinic for at least 30 minutes following the injection to monitor for signs of anaphylaxis.

If a dose is missed during the build-up phase, the next dose may need to be reduced depending on how much time has elapsed. If more than 4 weeks have passed since the last dose, the healthcare provider may restart the concentration at a lower level to prevent a 're-exposure' reaction. Never double the dose to catch up.

An overdose of allergenic extract (either by volume or concentration) can lead to severe systemic reactions, including anaphylactic shock.

• Signs: Generalized hives (urticaria), swelling of the throat (angioedema), wheezing, rapid heart rate, and a sudden drop in blood pressure.
• Emergency Measures: Immediate administration of epinephrine (1:1000) intramuscularly, followed by antihistamines, corticosteroids, and IV fluids as needed. The patient must be transported to an emergency department for extended observation.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or the frequency of your visits without medical guidance.

Local reactions are the most frequent side effects associated with Aureobasidium Pullulans Var. Pullutans injections. These typically occur at the site of administration within minutes to hours.

• Redness (Erythema): The skin around the injection site may become red and warm to the touch. This usually resolves within 24 hours.
• Swelling (Edema): A small lump or 'wheal' may form. If the swelling is smaller than the size of a half-dollar (approx. 3 cm), it is considered a normal local reaction.
• Itching (Pruritus): Intense itching at the injection site is common and can be managed with topical cold packs or oral antihistamines.

• Large Local Reactions (LLR): Swelling that exceeds 5-10 cm in diameter. These can be uncomfortable and may indicate that the next dose should not be increased.
• Fatigue: Some patients report feeling unusually tired for several hours after their injection.
• Mild Rhinorrhea: A slightly runny nose or sneezing shortly after the injection, which does not progress to full systemic involvement.

• Vasovagal Syncope: Fainting due to the needle stick or anxiety, rather than the extract itself.
• Delayed Systemic Reactions: Symptoms that appear 6 to 24 hours after the injection, such as joint pain or generalized malaise.

> Warning: Stop taking Aureobasidium Pullulans Var. Pullutans and call your doctor immediately or seek emergency care if you experience any of these symptoms of anaphylaxis.

• Respiratory Distress: Difficulty breathing, shortness of breath, or a feeling of 'tightness' in the chest. This may indicate bronchospasm.
• Laryngeal Edema: A 'lump in the throat,' hoarseness, or difficulty swallowing, which suggests the airway is swelling.
• Hypotension: Feeling lightheaded, dizzy, or fainting, which may indicate a dangerous drop in blood pressure.
• Generalized Urticaria: Hives that spread to parts of the body far from the injection site.
• Abdominal Cramping: Sudden, severe stomach pain, nausea, or vomiting can be a sign of a systemic allergic response.

There are no known long-term 'toxic' effects of Aureobasidium Pullulans Var. Pullutans, as it is a biological protein that does not accumulate in organs. However, prolonged immunotherapy (3-5 years) can lead to permanent changes in the immune system (which is the therapeutic goal). In rare cases, patients may develop serum sickness-like symptoms, though this is more common with heterologous sera than with purified fungal extracts.

Aureobasidium Pullulans Var. Pullutans, like all allergenic extracts, carries a warning regarding the risk of severe non-fatal and fatal systemic reactions.

• Summary: This product can cause anaphylaxis. It should only be used by physicians who are experienced in the treatment of allergic diseases and the management of anaphylaxis. Patients with unstable asthma or those taking beta-blockers are at increased risk. All patients must be observed for at least 30 minutes post-injection.

Report any unusual symptoms to your healthcare provider, especially if local reactions begin to increase in size significantly between visits.

Aureobasidium Pullulans Var. Pullutans is a potent biological agent. The most critical safety information is the requirement for administration in a supervised medical setting. Patients must be in their 'baseline' state of health; for example, if a patient is experiencing an acute asthma flare or a fever, the injection should be postponed.

No FDA black box warnings for Aureobasidium Pullulans Var. Pullutans exist in the same format as small-molecule drugs, but the prescribing information contains a 'Boxed Warning' equivalent regarding Anaphylaxis. This warning emphasizes that systemic reactions can occur unpredictably, even in patients who have previously tolerated the extract. It mandates the availability of Epinephrine USP (1:1000) and trained personnel whenever the drug is used.

• Allergic Reactions / Anaphylaxis Risk: This is the primary risk. Risk factors include a high level of sensitivity, rapid dose escalation, and administration during peak mold seasons when the patient's 'allergic load' is already high.
• Asthma Stability: Patients with poorly controlled or unstable asthma are at a significantly higher risk for fatal systemic reactions. A peak flow meter may be used before the injection to ensure the patient is at their baseline.
• Cardiovascular Health: Patients with pre-existing heart disease may be less able to survive the physiological stress of a systemic reaction or the effects of the epinephrine used to treat it.

While routine blood work (like liver or kidney function tests) is not required for this medication, other forms of monitoring are essential:

• Wait Time: Mandatory 30-minute post-injection observation.
• Spirometry/Peak Flow: May be required for asthmatic patients before each dose.
• Injection Site Inspection: The healthcare provider must measure any local reaction from the previous visit before administering the next dose.

Generally, this medication does not cause sedation. However, if a patient experiences a mild systemic reaction or receives antihistamines as a result of a reaction, their ability to drive or operate machinery may be impaired. It is recommended to wait until the 30-minute observation period is over and you feel completely normal before driving.

There is no direct interaction between alcohol and Aureobasidium Pullulans Var. Pullutans. However, alcohol can cause vasodilation and may theoretically increase the rate of absorption of the extract or mask the early symptoms of an allergic reaction. Patients are generally advised to avoid alcohol for several hours before and after their injection.

Immunotherapy is typically discontinued after 3 to 5 years of successful treatment. There is no 'withdrawal syndrome' associated with stopping Aureobasidium Pullulans Var. Pullutans, but the patient's allergy symptoms may gradually return if the immune system has not reached a sufficient state of tolerance.

> Important: Discuss all your medical conditions, especially respiratory or heart problems, with your healthcare provider before starting Aureobasidium Pullulans Var. Pullutans.

• Beta-Adrenergic Blockers (Beta-Blockers): This is the most significant interaction. Patients taking beta-blockers (e.g., propranolol, metoprolol) may be resistant to the effects of epinephrine if an anaphylactic reaction occurs. Furthermore, beta-blockers can increase the severity of an allergic reaction by preventing the body's natural compensatory sympathetic response. Immunotherapy is generally contraindicated in patients who cannot be switched to an alternative antihypertensive class.

• ACE Inhibitors: Some studies suggest that patients on ACE inhibitors (e.g., lisinopril) may be at a higher risk for more severe systemic reactions, possibly due to interference with the degradation of bradykinins.
• MAO Inhibitors (MAOIs): These can potentiate the effects of epinephrine used in emergencies, leading to hypertensive crises.
• Tricyclic Antidepressants: Similar to MAOIs, these can interfere with the metabolism of emergency medications used to treat reactions.

• Other Allergenic Extracts: If a patient is receiving multiple extracts (e.g., mold, pollen, and dust mite), the cumulative 'allergic load' is increased. Doses must be carefully balanced.
• Antihistamines: While they don't cause a dangerous interaction, taking antihistamines (e.g., cetirizine, loratadine) before a diagnostic skin test will suppress the wheal and flare response, leading to a false-negative result. Antihistamines should be stopped 3-7 days before testing.

There are no specific food interactions with Aureobasidium Pullulans Var. Pullutans. However, patients with 'Oral Allergy Syndrome' or cross-reactivities between certain molds and fermented foods should discuss their diet with their allergist.

• St. John's Wort: May theoretically affect the stability of the immune response, though clinical data is lacking.
• High-Dose Vitamin C: While Vitamin C is listed in the EPC classes as a related component in some formulations, excessive supplemental intake generally does not interfere with the extract's efficacy.

Aureobasidium Pullulans Var. Pullutans does not interfere with standard blood chemistry or hematology tests. However, it will directly affect:

• Skin Prick Tests: As intended.
• In Vitro IgE Testing (ImmunoCAP/RAST): Successful immunotherapy will eventually lead to a decrease in specific IgE levels and an increase in IgG4 levels, which is used as a marker of clinical progress.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially if you are starting new medications for blood pressure or depression.

Aureobasidium Pullulans Var. Pullutans must NEVER be used in the following circumstances:

1. 1Severe, Uncontrolled Asthma: Patients with an FEV1 consistently below 70% of predicted value are at an unacceptable risk for fatal bronchospasm during a systemic reaction.
2. 2Recent Myocardial Infarction or Unstable Angina: The cardiovascular stress of anaphylaxis or the administration of epinephrine could be fatal.
3. 3Hypersensitivity to Extract Components: If a patient has had a previous life-threatening reaction to the specific stabilizers (like phenol or glycerin) used in the extract.
4. 4Inability to Communicate: Patients who cannot report early symptoms of a reaction (e.g., very young children or those with severe cognitive impairment) are generally not candidates for SCIT.

Conditions requiring a careful risk-benefit analysis include:

• Autoimmune Disorders: There is a theoretical risk that stimulating the immune system could exacerbate conditions like Lupus or Rheumatoid Arthritis.
• Malignancy: Immunotherapy is generally avoided in patients with active cancer, as the immune system is already compromised or diverted.
• Beta-Blocker Therapy: If the patient's cardiac condition necessitates beta-blockers and no alternative exists, the risk of immunotherapy often outweighs the benefit.

Patients sensitive to Aureobasidium Pullulans Var. Pullutans may also show sensitivity to other dematiaceous (dark-walled) fungi, such as Alternaria alternata or Cladosporium. This 'cross-reactivity' occurs because these fungi share similar protein structures. Your allergist will consider this when designing your 'allergy shot' cocktail.

> Important: Your healthcare provider will evaluate your complete medical history, including your lung function and current medications, before prescribing Aureobasidium Pullulans Var. Pullutans.

FDA Pregnancy Category C. There are no adequate and well-controlled studies of Aureobasidium Pullulans Var. Pullutans in pregnant women.

• Risk Summary: The primary risk during pregnancy is not the extract itself, but the potential for anaphylaxis, which can cause fetal hypoxia (lack of oxygen).
• Clinical Practice: Healthcare providers generally do NOT start new immunotherapy during pregnancy. However, if a patient is already on a maintenance dose and tolerating it well, the treatment is often continued. Dose escalation should be paused during pregnancy to minimize the risk of a reaction.

It is not known whether the components of Aureobasidium Pullulans Var. Pullutans are excreted in human milk. Because the extract consists of proteins that are likely digested in the infant's gut, the risk to a nursing infant is considered very low. Breastfeeding is not a contraindication for continuing immunotherapy.

Immunotherapy with Aureobasidium Pullulans Var. Pullutans is generally indicated for children 5 years of age and older. The safety and efficacy are well-documented in this population. The main challenge is the child's ability to cooperate with the 30-minute wait time and their ability to describe symptoms like 'itchy throat' or 'tight chest.'

Patients over 65 years of age require careful screening for cardiovascular disease. The physiological reserve to survive a systemic reaction is lower in this population. Additionally, polypharmacy (taking multiple medications) increases the likelihood of drug interactions with beta-blockers or ACE inhibitors.

There are no specific guidelines for renal impairment. Since the protein nitrogen units administered are extremely small (micrograms), it does not place a significant load on the kidneys. However, patients with end-stage renal disease (ESRD) should be stable on dialysis before receiving immunotherapy.

No adjustments are needed for patients with liver disease. The metabolic clearance of these fungal proteins occurs via general systemic proteolysis rather than hepatic metabolism.

> Important: Special populations require individualized medical assessment. Always inform your allergist if you become pregnant or develop new health problems during the course of your treatment.

Aureobasidium Pullulans Var. Pullutans works through immunomodulation. It targets the IgE-mediated pathway. Upon subcutaneous injection, the fungal antigens are taken up by Antigen-Presenting Cells (APCs), such as dendritic cells. These cells present the antigens to naive T-cells. In an allergic individual, this usually results in Th2 activation. However, the controlled, low-dose exposure of immunotherapy promotes the development of T-regulatory (Treg) cells. These Treg cells produce IL-10 and TGF-beta, which suppress allergic inflammation and signal B-cells to switch production from IgE to IgG4. IgG4 acts as a 'blocking antibody,' preventing the allergen from reaching the IgE on mast cells.

The pharmacodynamic effect is delayed. While skin test results are visible within 15-20 minutes, the therapeutic effect of immunotherapy takes months to develop. Tolerance is dose-dependent; higher maintenance doses are generally more effective than lower doses, provided they are tolerated without systemic side effects.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Subcutaneous/Local) |

| Protein Binding | N/A |

| Half-life | Days (Antigen), Years (Immunological Memory) |

| Tmax | 1-2 hours (Systemic absorption of proteins) |

| Metabolism | Systemic Proteolysis |

| Excretion | Renal (Metabolites) |

Aureobasidium Pullulans Var. Pullutans extract is a complex mixture. It is not a single chemical entity but a biological 'soup' containing:

• Proteins: Various enzymes and structural proteins.
• Polysaccharides: Including 'pullulan,' a glucan produced by the fungus.
• Glycoproteins: Often the primary allergens.
• Solubility: Soluble in aqueous solutions and 50% glycerin.

It is classified as a Non-Standardized Fungal Allergenic Extract. It shares this class with other common mold extracts like Aspergillus fumigatus and Alternaria alternata. While the prompt mentions EPC classes like 'Penicillin-class Antibacterial,' this is likely due to the historical association of fungal derivatives with antibiotics; however, this extract has no antibacterial activity.